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CIRCULATION OF HUMAN PAPILLOMAVIRUS (HPV) GENOTYPES IN WOMEN FROM CÓRDOBA, 
ARGENTINA, WITH SQUAMOUS INTRAEPITHELIAL LESIONS
Raul Fernando VENEZUELA, Ana Ximena KIGUEN, Maria Celia FRUTOS & Cecilia Gabriela CUFFINI
SUMMARY
Human papillomavirus (HPV) can induce a wide spectrum of squamous intraepithelial lesions (SIL) of varying severity. The aim 
of the present study was to establish the frequency of HPV infection and identify the genotypes circulating in women from Córdoba, 
Argentina, in relation to age and cytology. A total of 186 women, between 18 and 65 years old, with antecedents of SIL, underwent a 
pelvic examination and had cervical cells collected for cytology and HPV DNA detection. Ninety-six samples (51.6%) were positive 
for HPV detection, and sixty-three (65.6%) of them showed the presence of at least one HR-HPV. Low- and high-grade SIL showed 
significant association in patients younger than 35 years of age. We found 18 different genotypes, with a greater presence of HR-HPV. 
Genotypes 16 and 6 were the most frequent. Seven (7.3%) multiple infections, 85.7% of which had at least one HR-HPV, were detected. 
The detection of a large number of different HPV genotypes is a warning sign. It is thus necessary to strengthen the monitoring of 
the circulation of high-risk genotypes, currently less prevalent in intraepithelial lesions, as a control measure for the possible impact 
of the implementation of vaccines against genotypes 16 and 18.
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INTRODUCTION
Human Papillomavirus (HPV) can induce a wide spectrum of 
squamous intraepithelial lesions of varying severity. The prevalence of 
HPV genital infection, which is the most common sexually transmitted 
infection worldwide, depends on the woman’s age and the method of 
detection5. Numerous studies have reported that certain types of HPV 
are the main cause of cervical cancer. More than 40 genotypes have been 
identified in the anogenital tract. Depending on their association with 
low/high-grade squamous intraepithelial lesions or invasive carcinomas, 
they can be grouped into low-risk (LR-HPV), such as HPV 6 and 11, and 
high-risk HPV (HR-HPV), such as HPV 16, 18, 31, and 3318,23.
The pathogenesis of cervical cancer begins as a slow process that 
disrupts the differentiation of the cervical squamous epithelium, causing 
changes in its structure and physiology35.
Cervical cell dysplasia, which is evidenced by alterations in the 
shape, size and organization of the epithelium, is caused as a result of 
infection with HPV20,35.
By means of the Bethesda System31, these lesions may be classified 
as: atypical squamous cells of undetermined significance (ASCUS), 
low-grade squamous intraepithelial lesions (LSIL), high-grade squamous 
intraepithelial lesions (HSIL) or Squamous Cell Carcinoma (SCC).
The knowledge of HPV genotypes in our female population is 
important for establishing strategies to prevent SCC and control squamous 
intraepithelial lesions, including the molecular diagnosis of the virus and 
vaccination. Thus, considering the recent inclusion of anti-HPV vaccines 
in the National Vaccination Calendar, the monitoring of circulating 
genotypes should be sustained over time, since the possible existence of 
mechanisms of immune pressure would result in a decreased circulation 
of the genotypes listed in the vaccines and the consequent increase in the 
frequency of detection of those not included in the formulation.
The goal of the present study was to establish the frequency of HPV 
infection and identify the genotypes circulating in women in the city of 
Córdoba, Argentina, in relation to age and cytology.
MATERIALS AND METHODS
A total of 186 women with antecedents of squamous intraepithelial 
lesions who attended private clinics and public health centers in Córdoba, 
Argentina, between May 2008 and May 2010 were invited to participate 
in a cross-sectional study on cervical HPV infection. At the beginning 
of the study, participants answered a questionnaire and signed a written 
consent form, in accordance with the Ethics Committee of the School of 
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Medical Sciences of the University of Córdoba. Participants were then 
subjected to a pelvic examination for the collection of cervical cells for 
cytology and HPV-DNA detection.
The samples were collected in 500 μL phosphate-buffered saline 
(PBS). DNA was extracted using the commercial AccuPrep Genomic 
DNA Extraction Kit (Bioneer Inc., CA, USA), in accordance with the 
manufacturer’s instructions.
A 450-bp segment, corresponding to the L1 region of the viral 
genome, was amplified by PCR, using the degenerate primers MY09 and 
MY11 (Integrated DNA Technology - USA)3. The product was detected 
by electrophoresis in agarose gel at 1.5% using a U.V. transilluminator. 
The β-globin gene was used as a DNA preservation marker12. Negative 
samples were considered inadequate.
HPV-DNA positive samples were typed by Restriction Fragment 
Length Polymorphism (RFLP) according to BERNARD et al., 1994. 
Briefly, aliquots of the PCR products obtained using the degenerate 
consensus primers MY09–MY11, targeting a region of approximately 
450 bp in length in the L1 ORF of the viral genome, were mixed with 
seven different restriction enzymes (Bam HI, Hae III, Dde I, Pst I, Hinf 
I, Sau III, and Rsa I) in separate reactions. The digestion products were 
separated by electrophoresis in 3% agarose gel and the pattern obtained 
compared with published data3.
Statistical analysis was carried out with InfoStat version 2011, with 
a significance level of 5% [95% CI]17. 
In order to estimate the probabilities of occurrence, we calculated 
the frequencies for the different genotypes, ages and cytological 
characteristics.
Chi-square (c2) tests for independence were conducted to determine 
the association between different age groups, cytological characteristics, 
HPV genotype and risk. At the same time, logistic regressions were 
performed to determine association between age, type of lesion (LSIL/
HSIL) and genotype. For the latter, we worked with genotypes 6, 11, 
16 and 18.
RESULTS
The age of the patients ranged between 18 and 65 years old (mean 
age 31.13 years) and the distribution by age was as follows: < 25 years 
(x ̅22.1 SD 1.79) = 35 (18.8%), 25-34 years (x̅ 29.5 SD 2.76) = 96 (51.6), 
35-44 years (x̅ 38.9 SD 2.89) = 28 (15.1%) and ≥ 45 years (x̅ 48.7 SD 
5.71) = 11 (5.9%). Age information was not available for sixteen of the 
samples (8.6%). These samples were thus excluded from the age analysis.
The Papanicolaou smears were stained and interpreted locally by a 
team of cytopathologists and the results were classified according to the 
Bethesda System. LSIL was diagnosed in 120 women (64.5%), HSIL 
in 42 (22.6%), ASCUS in 16 (8.6%), and SCC in one (0.5%). Seven 
samples (3.8 %) were normal.
All of the samples showed gene amplification for the beta-globin. 
Ninety-six samples (51.6%) were positive for HPV detection, and 
sixty-three (65.6%) of them (i.e. 33.9% of all samples) showed the 
presence of at least one HR-HPV.
Table 1 shows the detection of HPV (HR-HPV and LR-HPV) in 
function of age, compared with the cytological classification.
Although the overall analysis did not show predominance of any of 
the cytological classifications by age group (c2 = 17.9, p = 0.3276), in the 
analysis of independence between the age group and the type of lesion 
(HSIL and LSIL), we found a significant association with women under 
35 years (c2 = 4.9, p = 0.026 OR = 0.30, 0.10 to 0.87).
Table 1
Age distribution and cytology
< 25 25-34 35-44 ≥45 WITHOUT AGE TOTAL
nº Pos %  nº Pos % nº Pos %  nº Pos % nº Pos % nº Pos %
ASCUS 2 2 (100.0)  7  3 (42.8)  3 - -  1 1 (100.0) 3 1 (33.3)  16 7 (43.7)
HR-HPV 2 (100.0)  - - - - - - 1 (100.0) 3 (42.9)
LR-HPV - - 3 (100.0) - - 1 (100.0) - - 4 (57.1)
LSIL 23 14 (60.8)  57 26 (45.6) 21 8 (38.1)  8 5 (62.5) 11 4 (36.4) 120 57 (47.5)
HR-HPV 11 (78.6) 17 (65.4) 2 (25.0) 1 (20.0) 2 (50.0) 33 (57.9)
LR-HPV 3 (21.4)  9 (34.6) 6 (75.0) 4 (80.0) 2 (50.0) 24 (42.1)
HSIL 7 4 (57.1)  30 23 (76.6)  3 2 (66.7)  1 1 (100.0) 1 - -  42 30 (71.4)
HR-HPV 2 (50.0) 21 (91.3) 2 (100.0) 1 (100.0) - - 26 (86.7)
LR-HPV 2 (50.0) 2 (8.7) - - - - - - 4 (13.3)
TOTAL 35  21 (60.0)  96 52 (54.2) 28 10 (35.7) 11 7 (63.6) 16 6 (37.5) 186 96 (51.6)
HR-HPV 16 (76.2) 38 (73.1) 4 (40.0) 2 (28.6) 3 (50.0) 63 (65.6)
LR-HPV 5 (23.8) 14 (26.9) 6 (60.0) 5 (71.4) 3 (50.0) 33 (34.4)
The multiple infections that had at least one HR-HPV were considered to be HR-HPV because of their clinical importance. Data not included in the table: Normal, 2 
patients, < 25, 2 patients, 25-34, 1 patient, 35-44, 1 patient, ≥ 45 and Without Age, 1 that was LR-HPV. SCC: 1 patient < 25 HR-HPV. 
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The HSIL lesion type had the highest detection of HPV (71.4%) and 
frequency of HR-HPV (86.7%). However, the distribution of HR-HPV 
did not show a statistically significant association with the type of lesion 
(c2 = 2.7, p = 0.0995 OR = 0.43, 0.16, 1.16). In spite of this, except for 
the group < 25 years old, the detection rate of HR-HPV in HSIL was 
higher than 90%.
In addition, HPV detection exceeded 50% in all age groups, except 
for the 35-44 year old group; in the group < 25 years old we detected the 
largest percentage of HR-HPV (76.2%), most of which (78.6%) were 
detected in LSIL.
Table 2 shows the distribution of genotypes according to the 
cytological classification. The most prevalent genotypes were 16 and 6. 
Together, these two genotypes reached 50% of the total (52/104, including 
multiple infections). Both were identified in all cytological classifications, 
except for genotype 6 in SCC and 16 in normal.
Genotype 16 was the most prevalent in SCC and HSIL, whereas 
genotype 6 was the most prevalent in normal samples as well as in 
ASCUS and LSIL.
The second most prevalent LR-HPV was genotype 11 (8.3%), 
which was detected only in ASCUS and LSIL, whereas the second most 
prevalent HR-HPV were genotypes 18, 52 and 58 (6.2% each), which 
were found in LSIL and HSIL, with a higher percentage in the latter.
The four most frequent genotypes in HSIL were 16, 52, 18 and 58, 
whereas the most frequent in LSIL were 6, 16, 11 and 31.
In the logistic regression analysis for lesion type, age and genotype, 
HPV 16, 11 and 18 were present in all age groups and lesion types, 
without statistical association. In contrast, genotype 6 showed association 
with LSIL (β = -1.65, p value = 0.0417, OR = 0.19, 0.04-0.94), but such 
association was not observed with the different ages (Table 3).
RFLP analysis detected the presence of seven (7.3%) multiple 
infections, 85.7% of which had at least one HR-HPV, being genotype 
16 the most frequent one. The distribution of these infections according 
to the lesion was: LSIL 57.1%, HSIL 28.6% and ASCUS 14.3%, but the 
frequencies of multiple infections vs. lesions did not show significant 
differences (c2 = 3.75, p value = 0.4409).
Six of these multiple infections (85.7%) were observed in women 
under 35 years old, more frequently in the 25-34 year old group (57.1%) 
(data not shown).
Figure 1 shows a comparison between the detection of genotypes 
included in the anti-HPV vaccine and of those not included in the 
formulation. The goodness-of-fit test shows statistically significant 
differences between pairs of columns: HR-HPV 16 and 18 vs. HR-HPV 
genotypes other than 16 and 18 (c2 = 6.00; p value = 0.0143), LR-HPV 
6 and 11 vs. LR-HPV genotypes other than 6 and 11 (c2 =15.04; p value 
Table 2
Distribution of genotypes vs cytology classification
Genotype Total Normal ASCUS LSIL HSIL SCC
16 25 (26.0) - 1 (14.3) 14 (24.6) 9 (30.0) 1 (100.0)
 6 21 (21.9) 1 (100.0) 3 (42.8) 15 (26.3) 2 (6.7) -
11 8 (8.3) - 1 (14.3) 7 (12.3) - -
18 6 (6.2) - - 2 (3.5) 4 (13.3) -
58 6 (6.2) - - 2 (3.5) 4 (13.3) -
52 6 (6.2) - - 1 (1.7) 5 (16.7) -
31 5 (5.2) - - 3 (5.3) 2 (6.7) -
45 3 (3.1) - 1 (14.3) 2 (3.5) - -
33 2 (2.3) - - 1 (1.7) 1 (3.3) -
35 2 (2.3) - - 2 (3.5) - -
59+61 2 (2.3) - - 1 (1.7) 1 (3.3) -
51 1 (1.0) - - 1 (1.7) - -
53 1 (1.0) - - - 1 (3.3) -
59 1 (1.0) - - 1 (1.7) - -
61 1 (1.0) - - 1 (1.7) - -
62 1 (1.0) - - 1 (1.7) - -
16+56 1 (1.0) - - 1 (1.7) - -
16+6 1 (1.0) - - 1 (1.7) - -
16+61+62 1 (1.0) - 1 (14.3) - - -
16+64 1 (1.0) - - 1 (1.7) - -
6+54 1 (1.0) - - - 1 (3.3) -
TOTAL 96 (100.0) 1 (1.0) 7 (7.3) 57 (59.4) 30 (31.3) 1 (1.0)
Table 3
Logistic regression analysis for lesion type, age and genotype
GENOTYPE
Lesion (HSIL-LSIL) Age
 β p (<0.05) OR 95% CI AIC β p (<0.05) OR 95% CI AIC
6 -1.65 0.0417 0.19 0.04 - 0.94 124.98 0.01 0.8082 0.99 0.92 - 1.07 131.04
11 0.001 0.5534 1.00 1.00 - 1.00 125.07 0.01 0.8549 0.99 0.93 - 1.07 131.38
16 0.28 0.5520 1.32 0.49 - 3.61 129.75  -0.01 0.8121 1.01 0.94 - 1.08 135.79
18 1.36 0.1318 3.91 0.66 - 23.07 126.00 -0.009 0.9701 1.00 0.94 - 1.07 132.49
AIC: Akaike’s Information Criterion
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< 0.001) and 6, 11, 16 and 18 vs. remaining HPV (c2 = 12.04; p value 
< 0.001).
DISCUSSION
In the present study, the percentage of HPV detection (51.6%) was 
similar to that described in the region (between 41% and 64%). Similarly, 
HR-HPV detection (65%) was within the range previously reported 
(30-73%) for the same population using the same detection method13,29.
Notably, as also observed in studies carried out in Concordia, 
Argentina, the frequency of HR-HPV decreases as age increases, possibly 
associated with the development of immunity against these genotypes22.
Our work highlights the importance of HPV screening in assessing 
the prognosis, control of the lesion, and implementation of the treatment11, 
since a high percentage (57.9%) of HR-HPV was detected in LSIL, 
13.3% of HSIL was positive for LR-HPV and 28.6% of HSIL was 
negative for HPV.
Although the high percentage of HR-HPV in LSIL coincides with 
the results of a meta-analysis carried out in different regions of the 
world8, there is no evidence of a statistically significant difference, thus 
suggesting that both LR-HPV and HR-HPV can be found in this lesion.
The lack of agreement in HPV detection in samples with normal 
classification may be because in our work the number of patients who 
had normal smears was very low. 
Although we detected 18 different genotypes, most of which were 
HR-HPV, the distribution of genotypes in our study was polarized 
between HPV 6 and 16, since the frequencies of these genotypes were 
respectively two and three times higher than the remaining ones (Table 2).
The higher frequency of detection of genotype 16 is in agreement 
with that found in previous reports carried out in the region and others 
carried out in the Iberian Peninsula, with some variations in the detection 
rate of the remaining genotypes2,4,6,9,22.
We found no statistical association between HPV 16 and the type of 
lesion (by logistic regression analysis, β: 0.28, p: 0.5820). We conclude 
that, in agreement with what was previously reported15,33, HPV 16 can 
be found in HSIL and LSIL. However, in our population, genotype 16 
was found mostly in HSIL.
In agreement with the findings of other authors21, HR-HPV 16, 18, 
52 and 58 were most frequently detected in HSIL. We also found that 
the only LR-HPV genotypes found in HSIL were 6 and 54, the latter of 
which was found in multiple infections with HPV 6.
Among the genotypes not present in the development of vaccines, 
the most frequently detected were HPV 52 and HPV 58 (Table 2). These 
were more common in HSIL and observed in the 25-34 age group (data 
not shown). 
Some prevalence studies have indicated that the DNA of HPV 
52 is present in approximately 2% of all cases of cervical squamous 
intraepithelial lesions28,29 and that the presence of HPV 58 for these 
lesions ranges from 6% to 20%, which is the range within which these 
genotypes were detected in our work13,24,25,26.
The detection of multiple infections was lower than that in other 
regions, and at least one HR-HPV was detected in most multiple 
infections22,29. Some studies have reported a close association between 
multiple infections and the increase in the severity of the lesion10,19. 
However, in agreement with other studies, most of the multiple infections 
in our work were detected in LSIL (57.1%). This could be due to the 
fact that in high-grade lesions, the viral DNA is integrated into the host’s 
genome, which leads to partial loss of the region of the L1 gene, to which 
the amplification by the MY09/11 primer set is directed14,32. 
Another interesting aspect of the presence of these infections is the 
generation of an environment that favors potential recombination, which 
may have a major impact on pharmacogenomics and primary prevention 
with the implementation of existing vaccines1. 
It is noteworthy that the variety of HR-HPV is about twice that of 
LR-HPV (11 vs. 7) and, as shown in Fig. 1, although immunization 
with existing vaccines would cover more than 50% of infections, a high 
percentage (45.3%) of HR-HPV infections would not be prevented by 
these vaccines. Although the cross-protection data are encouraging16,30, 
the titers of the neutralizing antibodies for the genotypes not included in 
the formulation are about ten times lower than those for the genotypes 
that are included. This generates uncertainty about whether they will 
disappear more rapidly than the specific antibodies. It has also been 
reported that the protection against HPV 52 and HPV 58 (two of the four 
most frequent HR-HPV in our study) is not significant. These data have 
led some authors to infer that the cross-protection seems to be limited27,30. 
The distribution of HPV among different populations is not 
homogeneous, and the interaction of human relations leads to viral 
dynamics that could alter the relative risk of each lesion in the population, 
especially when prevalence of HR-HPV is high34.
The information provided in the present study, which is the first to 
be carried out in Córdoba, Argentina, is important for the prevention of 
HPV, and highlights the importance of routine gynecological controls 
in women younger than 35 years of age, since this age group was found 
to be associated with LSIL and HSIL. Another important finding is that 
Data obtained from the HPV genotyping of patients from the current study.
Fig. 1 - Genotypes included in vaccines vs not included in vaccines.
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HR-HPV can be detected in all lesion types and age groups, with the 
aggravating circumstance that genotype 16 was found in a high percentage 
of LSIL, thus demonstrating the importance of virological diagnosis and 
preventive vaccination against this particular genotype.
RESUMEN
Circulación de genotipos de virus papiloma humano (VPH) 
en mujeres con lesiones intrepiteliales escamosas de Córdoba, 
Argentina
El papilomavirus humano (human papilloma, HPV) induce un amplio 
espectro de lesiones intraepiteliales escamosas (SIL) de variada severidad. 
Objetivo: conocer la frecuencia de infección por HPV y determinar 
los genotipos circulantes en mujeres de la ciudad de Córdoba, Argentina, 
en relación con la edad y la citología. Se realizó citología y detección 
de ADN-HPV en células cervicales de 186 mujeres de 18 a 65 años con 
antecedentes de SIL. Noventa y seis (51.6%) fueron positivas para la 
detección del HPV, de las cuales, en 63 (65.6%) se detectó la presencia 
de al menos, un HPV de Alto Riesgo (HR-HPV). Las SIL de alto grado 
(HSIL) y de bajo grado (LSIL) se asociaron a pacientes menores de 
35 años. Se hallaron 18 genotipos diferentes, con mayor presencia de 
HR-HPV. HPV 16 y 6 fueron más frecuentes y se detectaron 7 (7.3%) 
infecciones múltiples, 85.7% de éstas presentaron al menos un HR-HPV. 
La detección de un alto número de diferentes genotipos es una señal de 
alerta. Por tanto, es necesario fortalecer la vigilancia de los HR-HPV, 
actualmente menos frecuentes en las SIL, como medida de control del 
impacto que tendrá la implementación de las vacunas contra HPV 16 y 18.
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